bluebird bio, Inc.

BLUE13 Dec 2024
Healthcare
$0.39
-0.03 (-2.96%)
Lowest Today
$0.37
Highest Today
$0.41
Today’s Open
$0.39
Prev. Close
$0.39
52 Week High
$10.21
52 Week Low
$0.29
To Invest in bluebird bio, Inc.

bluebird bio, Inc.

Healthcare
BLUE13 Dec 2024
-0.03 (-2.96%)
1M
3M
6M
1Y
5Y
Low
$0.37
Day’s Range
High
$0.41
0.37
52 Week Low
$0.29
52-Week Range
52 Week High
$10.21
0.29
1 Day
-
1 Week
-15.72%
1 month return
+1.18%
3 month return
-36.26%
6 month return
-61.64%
1 Year return
-87.29%
3 Years return
-95.97%
5 Years return
-99.26%
10 Years return
-
Institutional Holdings
BlackRock Inc
7.94
Vanguard Group Inc
5.39
Vanguard Total Stock Mkt Idx Inv
3.02
iShares Russell 2000 ETF
2.79
Geode Capital Management, LLC
2.41
State Street Corp
1.98
ACATIS Datini Valueflex Fonds A
1.7

Market Status

Fundamentals
Market Cap
76.14 mln
PB Ratio
0.73
PE Ratio
0
Enterprise Value
373.9 mln
Total Assets
619.16 mln
Volume

Company Financials

Fund house & investment objective

Company Information
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Organisation
bluebird bio, Inc.
Employees
375
Industry
Biotechnology
CEO
Mr. Andrew  Obenshain
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step